Centerbridge, mubadala in talks to buy canaccord's UK wealth unit. October 20, 2026 at 7:35 AM PDT Updated on October 20, 2026 at 10:17 AM PDT Unlock the global benchmark for business news.

Stardust Metal Corp. has closed a brokered private placement offering, raising approximately $14.5 million in gross proceeds. The Toronto-based company, trading as TSXV: ZIGY, completed the financing with Canaccord Genuity Corp. as lead agent and sole bookrunner, alongside a syndicate including Velocity Trade Capital Ltd., CIBC World Markets Inc., and Clarus Securities Inc. The offering comprised 3,847,000 premium flow-through common shares at $2.725 each, generating roughly $10.5 million, and 2,051,000 common shares at $1.95 each, raising approximately $4 million. The company paid agents a 6% cash commission totalling $450,978. A strategic investor acquired 2,556,410 common shares, representing about 5% of outstanding shares, and entered into an investor rights agreement allowing participation in future equity financings.

Viking Therapeutics has priced an upsized $500 million concurrent public offering of common stock and convertible senior notes. The clinical-stage biopharmaceutical company will sell 7,857,143 shares at $35.00 per share and $225 million in 2% convertible senior notes due 2032. The offering size was increased from the previously announced $200 million for each component. The notes carry an initial conversion price of approximately $50.75 per share, representing a 45% premium over the public offering price. Viking estimates net proceeds of approximately $258.2 million from the common stock offering and $218 million from the note offering, after deducting underwriting discounts and expenses. The company intends to use proceeds for continued clinical development of its VK2735 and VK3019 programmes, as well as general research and development purposes. Morgan Stanley, JPMorgan, Jefferies, Leerink Partners, and William Blair are serving as joint book-running managers.